Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.74 |
| ▸ | CASP2 | P42575 | 1/20 | 0.57 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 4/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31734852 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL31358862 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL15986104 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL31711351 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL13855547 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL17392871 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL358468 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL308741 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL2386271 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL20162089 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3238698-B1 | COSMETIC COMPOSITION CONTAINING WATER-SOLUBLE MOISTURIZING COMPONENT AND ACYL BASIC AMINO ACID DERIVATIVE | AJINOMOTO KK (JP) | 2020-08-05 | — | — | EP | claimed |
| US-20200113799-A1 | POWDER MODIFYING AGENT, COMPOSITE POWDER AND MAKEUP COSMETIC | AJINOMOTO CO., INC. (JP) | 2020-04-16 | — | — | US | claimed |
| EP-3636247-A1 | POWDER MODIFYING AGENT, COMPOSITE POWDER AND MAKEUP COSMETIC | Ajinomoto Co., Inc. (JP) | 2020-04-15 | — | — | EP | claimed |
| EP-3238699-B1 | COSMETIC COMPOSITION CONTAINING ACYL BASIC AMINO ACID DERIVATIVE AND ANIONIC WATER-SOLUBLE POLYMER | AJINOMOTO KK (JP) | 2020-03-25 | — | — | EP | claimed |
| EP-3238700-B1 | COSMETIC COMPOSITION CONTAINING ACYL BASIC AMINO ACID DERIVATIVE AND INORGANIC POWDER | AJINOMOTO KK (JP) | 2020-02-19 | — | — | EP | claimed |
| US-20110262976-A1 | PRODUCTION OF R-a-LIPOIC ACID BY FERMENTATION USING GENETICALLY ENGINEERED MICROORGANISMS | INDIGENE PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | claimed |
| WO-2009091582-A1 | PRODUCTION OF R-α-LIPOIC ACID BY FERMENTATION USING GENETICALLY ENGINEERED MICROORGANISMS | INDIGENE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | claimed |
| JP-56018996-A | — | — | None | — | — | JP | disclosed |
| US-12605422-B2 | Compositions and methods for treating degenerative, age-related and trauma-induced disorders | S.I.S SHULOV INNOVATIVE SCIENCE LTD. (IL) | 2026-04-21 | — | — | US | disclosed |
| US-20260091077-A1 | COMPOSITIONS AND METHODS FOR TREATING DEGENERATIVE, AGE-RELATED AND TRAUMA-INDUCED DISORDERS | S.I.S. SHULOV INNOVATIVE SCIENCE LTD. (IL) | 2026-04-02 | — | — | US | disclosed |
| US-20260000598-A1 | ANTI-AGING COMPOSITIONS AND METHODS OF USE THEREOF | S.I.S. SHULOV INNOVATIVE SCIENCE LTD. (IL) | 2026-01-01 | — | — | US | disclosed |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| EP-4626396-A1 | A PERSONAL CARE COMPOSITION | Unilever IP Holdings B.V. (NL) | 2025-10-08 | — | — | EP | disclosed |
| WO-2009091582-A1 | PRODUCTION OF R-α-LIPOIC ACID BY FERMENTATION USING GENETICALLY ENGINEERED MICROORGANISMS | INDIGENE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20070298469-A1 | N-EPSILON-ACYL-L-LYSINE-SPECIFIC AMINOACYLASE | AJINOMOTO CO., INC. (JP) | 2007-12-27 | — | — | US | disclosed |
| EP-1852502-A1 | N -ACYL-L-LYSINE-SPECIFIC AMINOACYLASE | Ajinomoto Co., Inc. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-0021367-B1 | MURAMYLDIPEPTIDE DERIVATIVES, PROCESS FOR PREPARING SAID COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1983-04-06 | — | — | EP | disclosed |
| JP-S5618996-A | MURAMYLDIPEPTIDE DERIVATIVE | DAI ICHI SEIYAKU CO LTD | 1981-02-23 | — | — | JP | disclosed |
| EP-0021367-A1 | Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds | DAIICHI SEIYAKU CO., LTD. (JP) | 1981-01-07 | — | — | EP | disclosed |
| JP-S05618996-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000598-A1 | ANTI-AGING COMPOSITIONS AND METHODS OF USE THEREOF | ARGLU1, ARG1, CUTA | NOD1 2767/4885CASP2 1537/4885GNAI3 4789/4885 |
| US-12605422-B2 | Compositions and methods for treating degenerative, age-related and trauma-induced disorders | HTT, MAPT, APP | NOD1 2713/4885CASP2 334/4885GNAI3 3053/4885 |
| US-20260091077-A1 | COMPOSITIONS AND METHODS FOR TREATING DEGENERATIVE, AGE-RELATED AND TRAUMA-INDUCED DISORDERS | ROS1, PTMS, ARG1 | NOD1 379/4885CASP2 37/4885GNAI3 4093/4885 |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | GPR39, FABP2, GPR119 | NOD1 333/4885CASP2 3007/4885GNAI3 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.